209 related articles for article (PubMed ID: 35114109)
1. Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.
Soule EE; Yu H; Olson L; Naqvi I; Kumar S; Krishnaswamy S; Sullenger BA
Cell Chem Biol; 2022 Feb; 29(2):215-225.e5. PubMed ID: 35114109
[TBL] [Abstract][Full Text] [Related]
2. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
Bompiani KM; Monroe DM; Church FC; Sullenger BA
J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
[TBL] [Abstract][Full Text] [Related]
3. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions.
Kretz CA; Cuddy KK; Stafford AR; Fredenburgh JC; Roberts R; Weitz JI
Thromb Haemost; 2010 Jan; 103(1):83-93. PubMed ID: 20062917
[TBL] [Abstract][Full Text] [Related]
4. An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase.
Buddai SK; Layzer JM; Lu G; Rusconi CP; Sullenger BA; Monroe DM; Krishnaswamy S
J Biol Chem; 2010 Feb; 285(8):5212-23. PubMed ID: 20022942
[TBL] [Abstract][Full Text] [Related]
5. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway.
Gopinath SC; Shikamoto Y; Mizuno H; Kumar PK
Thromb Haemost; 2006 May; 95(5):767-71. PubMed ID: 16676065
[TBL] [Abstract][Full Text] [Related]
6. Notecarin D binds human factor V and factor Va with high affinity in the absence of membranes.
Newell-Caito JL; Laha M; Tharp AC; Creamer JI; Xu H; Maddur AA; Tans G; Bock PE
J Biol Chem; 2011 Nov; 286(44):38286-38297. PubMed ID: 21911491
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C.
Silveira JR; Kalafatis M; Tracy PB
Biochemistry; 2002 Feb; 41(5):1672-80. PubMed ID: 11814362
[TBL] [Abstract][Full Text] [Related]
8. Regulation of factor V by the anticoagulant protease activated protein C: Influence of the B-domain and TFPIα.
Ayombil F; Petrillo T; Kim H; Camire RM
J Biol Chem; 2022 Nov; 298(11):102558. PubMed ID: 36183835
[TBL] [Abstract][Full Text] [Related]
9. Factor V and thrombotic disease: description of a janus-faced protein.
Nicolaes GA; Dahlbäck B
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
[TBL] [Abstract][Full Text] [Related]
10. Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.
Petrillo T; Ayombil F; Van't Veer C; Camire RM
J Biol Chem; 2021; 296():100234. PubMed ID: 33376137
[TBL] [Abstract][Full Text] [Related]
11. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
Cramer TJ; Griffin JH; Gale AJ
Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
[TBL] [Abstract][Full Text] [Related]
12. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors.
Matsumoto T; Nogami K; Shima M
J Thromb Haemost; 2014 Sep; 12(9):1503-12. PubMed ID: 25041532
[TBL] [Abstract][Full Text] [Related]
13. Coagulation factor V and thrombophilia: background and mechanisms.
Segers K; Dahlbäck B; Nicolaes GA
Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
[TBL] [Abstract][Full Text] [Related]
14. Reversible regulation of aptamer activity with effector-responsive hairpin oligonucleotides.
Li N
J Lab Autom; 2013 Feb; 18(1):77-84. PubMed ID: 22651934
[TBL] [Abstract][Full Text] [Related]
15. Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.
Chabata CV; Frederiksen JW; Olson LB; Naqvi IA; Hall SE; Gunaratne R; Kraft BD; Que LG; Chen L; Sullenger BA
Nucleic Acid Ther; 2022 Jun; 32(3):139-150. PubMed ID: 35021888
[TBL] [Abstract][Full Text] [Related]
16. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
[TBL] [Abstract][Full Text] [Related]
17. A novel anticoagulant protein with high affinity to blood coagulation factor Va from Tegillarca granosa.
Jung WK; Jo HY; Qian ZJ; Jeong YJ; Park SG; Choi IW; Kim SK
J Biochem Mol Biol; 2007 Sep; 40(5):832-8. PubMed ID: 17927919
[TBL] [Abstract][Full Text] [Related]
18. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
Soule EE; Bompiani KM; Woodruff RS; Sullenger BA
Nucleic Acid Ther; 2016 Feb; 26(1):1-9. PubMed ID: 26584417
[TBL] [Abstract][Full Text] [Related]
19. Differential contributions of Glu96, Asp102 and Asp111 to coagulation factor V/Va metal ion binding and subunit stability.
Song J; Talbot K; Hewitt J; MacGillivray RT; Pryzdial EL
Biochem J; 2009 Aug; 422(2):257-64. PubMed ID: 19522703
[TBL] [Abstract][Full Text] [Related]
20. Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding.
Sun YH; Shen L; Dahlbäck B
Blood; 2003 Mar; 101(6):2277-84. PubMed ID: 12446455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
